Dec 01, 2021
|
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
|
|
Nov 19, 2021
|
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
|
|
Nov 12, 2021
|
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
|
|
Nov 02, 2021
|
Vertex Reports Third-Quarter 2021 Financial Results
|
|
Oct 26, 2021
|
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
|
|
Oct 22, 2021
|
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
|
|
Oct 19, 2021
|
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
|
|
Oct 18, 2021
|
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
|
|
Sep 13, 2021
|
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
|
|
Aug 26, 2021
|
Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
|
|
Aug 24, 2021
|
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
|
|
Aug 04, 2021
|
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
|
|
Jul 29, 2021
|
Vertex Reports Second-Quarter 2021 Financial Results
|
|
Jul 28, 2021
|
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
|
|
Jul 19, 2021
|
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
|
|
Jul 16, 2021
|
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
|
|
Jun 28, 2021
|
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
|
|
Jun 25, 2021
|
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
|
|
Jun 18, 2021
|
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
|
|
Jun 11, 2021
|
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
|
|